Morgan Stanley Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its price target lifted by Morgan Stanley from $222.00 to $231.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s target price points to a potential upside of 11.77% from the company’s previous close.

A number of other equities analysts also recently weighed in on the stock. Needham & Company LLC boosted their target price on shares of Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday, June 29th. HC Wainwright reiterated a “buy” rating and issued a $251.00 target price on shares of Biogen in a research note on Thursday. Sanford C. Bernstein lowered their price target on Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. Evercore started coverage on Biogen in a research note on Friday, May 15th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen upgraded Biogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Biogen presently has an average rating of “Moderate Buy” and a consensus target price of $223.36.

Biogen Price Performance

Biogen stock traded down $2.55 during trading hours on Thursday, hitting $206.68. 392,660 shares of the stock were exchanged, compared to its average volume of 1,290,783. The business’s 50-day moving average is $200.68 and its two-hundred day moving average is $190.37. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen has a 12 month low of $124.56 and a 12 month high of $219.72. The stock has a market capitalization of $30.51 billion, a P/E ratio of 22.22 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts expect that Biogen will post 11.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Biogen

Large investors have recently made changes to their positions in the company. LSV Asset Management increased its holdings in shares of Biogen by 3.3% during the fourth quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock worth $55,756,000 after purchasing an additional 9,976 shares during the period. Catalyst Funds Management Pty Ltd bought a new stake in shares of Biogen in the fourth quarter valued at approximately $2,006,000. Orbimed Advisors LLC acquired a new stake in Biogen during the first quarter worth approximately $11,293,000. Systematic Financial Management LP grew its position in Biogen by 256.3% during the fourth quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock worth $2,928,000 after buying an additional 11,970 shares in the last quarter. Finally, Contrarius Group Holdings Ltd bought a new position in Biogen during the 4th quarter worth $11,431,000. Institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of the $2.46 billion consensus estimate. Adjusted EPS of $3.60 also exceeded expectations, helped by a 24% increase in the Growth Portfolio and contributions from recently acquired Apellis products. Reuters report on Biogen earnings
• Positive Sentiment: Management raised its 2026 revenue outlook to mid-single-digit growth, while newer medicines—including rare-disease treatments and the Alzheimer’s drug Leqembi—are increasingly offsetting declines in legacy multiple sclerosis products. Analysts at Piper Sandler reaffirmed a Buy rating, and Needham maintained its $256 price target. Seeking Alpha report on Biogen outlook
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but retained a Neutral rating, indicating limited conviction despite a potentially higher valuation. Zacks also upgraded the stock from Strong Sell to Hold. Benzinga analyst update
• Negative Sentiment: GAAP net income plunged to $97.5 million from $634.8 million a year earlier, and diluted EPS fell to $0.66 from $4.33. The decline reflects acquisition-related and other costs, raising concerns that underlying profitability may be peaking even as revenue grows. Yahoo Finance analysis of Biogen profitability
• Negative Sentiment: Biogen’s 2026 adjusted EPS guidance of $12 to $13 is below the roughly $13.45 analyst consensus, and reports characterized the update as a reduction to the full-year profit outlook. Legacy MS sales remain under pressure, while Leqembi revenue narrowly missed expectations. Wall Street Journal report on Biogen guidance

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.